SJEPD032263_D1.RNA-Seq
EPN · Anaplastic EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Anaplastic EPN
- cancer_type
- EPN
- subtype
- Anaplastic EPN
- age_years
- 1.84
- e1_e2
- E2
- umap1_2d
- -5.389703478
- umap2_2d
- 2.153177041
- umap1_3d
- -1.147448913
- umap2_3d
- 3.748965986
- umap3_3d
- -0.911728777
- dataset
- EPN-StJude
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.440
- G2M_CHECKPOINT+0.420
- E2F_TARGETS+0.360
- PANCREAS_BETA_CELLS+0.350
- ANDROGEN_RESPONSE+0.330
- KRAS_SIGNALING_UP+0.330
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.320
- MYC_TARGETS_V1+0.320
- UV_RESPONSE_DN+0.320
- NOTCH_SIGNALING+0.310
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.500
- DNA_REPAIR-0.300
- INTERFERON_GAMMA_RESPONSE-0.300
- BILE_ACID_METABOLISM-0.270
- FATTY_ACID_METABOLISM-0.230
- XENOBIOTIC_METABOLISM-0.230
- PEROXISOME-0.190
- MYC_TARGETS_V2-0.170
- MYOGENESIS-0.090
- CHOLESTEROL_HOMEOSTASIS-0.050
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD030782_D1.RNA-Seq | EPN | EPN Tumor | 0.834 |
| 2 | ERR2278858 | — | — | 0.787 |
| 3 | TCGA-44-8119-01A-11R-2241-07 | — | cohortA3 | 0.751 |
| 4 | TCGA-EW-A1IW-01A-11R-A13Q-07 | — | A | 0.743 |
| 5 | BS_MKM0EEN1 | Diffuse intrinsic pontine glioma | — | 0.737 |
| 6 | TCGA-77-7337-01A-21R-2045-07 | — | cohortSQ1 | 0.736 |
| 7 | SRR1313150 | — | E | 0.733 |
| 8 | 247323b2-dc45-427e-bc41-c33f2fbbe77b | — | — | 0.732 |
| 9 | TCGA-55-7726-01A-11R-2170-07 | — | cohortSQ1 | 0.725 |
| 10 | TCGA-BH-A0C1-01B-11R-A12D-07 | — | A | 0.721 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.440 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.420 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.360 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.350 | Cobimetinib | — uncovered |
| ANDROGEN_RESPONSE | 0.330 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.330 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.320 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.320 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.320 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.310 | Inavolisib | — uncovered |
| HYPOXIA | 0.300 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.280 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.260 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.260 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.260 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.250 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.240 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.220 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.200 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.180 | Temsirolimus | — uncovered |